



**Final Appraisal Recommendation**

Advice No: 0220 – February 2020

**Dolutegravir/lamivudine (Dovato®) 50 mg/300 mg film-coated tablets**

**Limited submission by ViiV Healthcare UK Ltd**

**Recommendation of AWMSG**

**Dolutegravir/lamivudine (Dovato®) is recommended as an option for use within NHS Wales for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.**

**This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.**

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 3659), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 0220:  
Dolutegravir/lamivudine (Dovato®) 50 mg/300 mg film-coated tablets. February 2020.